VanEck CLO ETF (NYSEARCA:CLOI – Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $52.82 and traded as low as $52.76. VanEck CLO ETF shares last traded at $52.78, with a volume of 230,020 shares traded.
VanEck CLO ETF Trading Down 0.4%
The business’s 50-day moving average price is $52.89 and its two-hundred day moving average price is $52.82.
Institutional Trading of VanEck CLO ETF
Large investors have recently made changes to their positions in the company. Fifth Third Bancorp acquired a new stake in VanEck CLO ETF during the 1st quarter worth $32,000. FAS Wealth Partners Inc. lifted its holdings in VanEck CLO ETF by 38.8% during the first quarter. FAS Wealth Partners Inc. now owns 2,389 shares of the company’s stock worth $126,000 after acquiring an additional 668 shares in the last quarter. Redhawk Wealth Advisors Inc. grew its stake in VanEck CLO ETF by 15.9% in the second quarter. Redhawk Wealth Advisors Inc. now owns 5,603 shares of the company’s stock valued at $297,000 after acquiring an additional 768 shares during the period. Ascension Capital Advisors Inc. grew its stake in VanEck CLO ETF by 19.5% in the first quarter. Ascension Capital Advisors Inc. now owns 4,780 shares of the company’s stock valued at $252,000 after acquiring an additional 781 shares during the period. Finally, Waverly Advisors LLC grew its stake in VanEck CLO ETF by 4.8% in the second quarter. Waverly Advisors LLC now owns 19,869 shares of the company’s stock valued at $1,052,000 after acquiring an additional 909 shares during the period.
VanEck CLO ETF Company Profile
The VanEck CLO ETF (CLOI) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is actively managed to invest in collateralized loan obligations (CLOs) of any maturity. While targeting USD-denominated high-quality CLOs, the fund may still hold high-yield bonds in foreign currency. CLOI was launched on Jun 21, 2022 and is managed by VanEck.
Further Reading
- Five stocks we like better than VanEck CLO ETF
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for VanEck CLO ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck CLO ETF and related companies with MarketBeat.com's FREE daily email newsletter.
